Inhaled Corticosteroids and the Pneumonia Risk in Patients With Chronic Obstructive Pulmonary Disease: A Meta-analysis of Randomized Controlled Trials
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Inhaled Corticosteroids and the Pneumonia Risk in Patients With Chronic Obstructive Pulmonary Disease: A Meta-analysis of Randomized Controlled Trials
Authors
Keywords
-
Journal
Frontiers in Pharmacology
Volume 12, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-06-29
DOI
10.3389/fphar.2021.691621
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Risk of Pneumonia with Different Inhaled Corticosteroids in COPD Patients: A Meta-Analysis
- (2020) Qian Zhang et al. COPD-Journal of Chronic Obstructive Pulmonary Disease
- Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD
- (2020) Klaus F. Rabe et al. NEW ENGLAND JOURNAL OF MEDICINE
- Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2019 Report: Future Challenges
- (2019) José Luis López-Campos et al. ARCHIVOS DE BRONCONEUMOLOGIA
- Inhaled corticosteroids and risk of pneumonia in patients with chronic obstructive pulmonary disease: A meta-analysis of randomized controlled trials
- (2019) Mingjin Yang et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Long-Term Safety and Efficacy of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD
- (2019) Masakazu Ichinose et al. International Journal of Chronic Obstructive Pulmonary Disease
- Long-term Triple Therapy De-escalation to Indacaterol/Glycopyrronium in COPD Patients (SUNSET): a Randomized, Double-Blind, Triple-Dummy Clinical Trial
- (2018) Kenneth R Chapman et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Association of Inhaled Corticosteroids and Long-Acting β-Agonists as Controller and Quick Relief Therapy With Exacerbations and Symptom Control in Persistent Asthma
- (2018) Diana M. Sobieraj et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial
- (2018) Alberto Papi et al. LANCET
- Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD
- (2018) David A. Lipson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Budesonide/formoterol MDI with co-suspension delivery technology in COPD: the TELOS study
- (2018) Gary T. Ferguson et al. EUROPEAN RESPIRATORY JOURNAL
- Efficacy and safety of the direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone in non-frequently exacerbating COPD patients: The FLASH randomized controlled trial
- (2018) Peter A. Frith et al. RESPIROLOGY
- A randomized trial of symptom-based management in Japanese patients with COPD
- (2018) Tomoko Betsuyaku et al. International Journal of Chronic Obstructive Pulmonary Disease
- Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial
- (2018) Gary T Ferguson et al. Lancet Respiratory Medicine
- Long-term use of inhaled corticosteroids and risk of upper respiratory tract infection in chronic obstructive pulmonary disease: a meta-analysis
- (2017) Mingjin Yang et al. INHALATION TOXICOLOGY
- Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial
- (2017) Jørgen Vestbo et al. LANCET
- Inhaled Corticosteroid use and the Risk of Pneumonia and COPD Exacerbations in the UPLIFT Study
- (2017) Jaymin B. Morjaria et al. LUNG
- Effect of budesonide/formoterol pressurized metered-dose inhaler on exacerbations versus formoterol in chronic obstructive pulmonary disease: The 6-month, randomized RISE (Revealing the Impact of Symbicort in reducing Exacerbations in COPD) study
- (2017) Gary T. Ferguson et al. RESPIRATORY MEDICINE
- A randomised, phase III trial of once-daily fluticasone furoate/vilanterol 100/25 μg versus once-daily vilanterol 25 μg to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD
- (2017) Thomas M. Siler et al. RESPIRATORY MEDICINE
- Fluticasone propionate/formoterol for COPD management: a randomized controlled trial
- (2017) A Papi et al. International Journal of Chronic Obstructive Pulmonary Disease
- A randomized trial of once-daily fluticasone furoate/vilanterol or vilanterol versus placebo to determine effects on arterial stiffness in COPD
- (2017) Surya Bhatt et al. International Journal of Chronic Obstructive Pulmonary Disease
- Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015
- (2017) Joan B Soriano et al. Lancet Respiratory Medicine
- Efficacy and safety of aclidinium/formoterolversussalmeterol/fluticasone: a phase 3 COPD study
- (2016) Claus Vogelmeier et al. EUROPEAN RESPIRATORY JOURNAL
- Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial
- (2016) Jørgen Vestbo et al. LANCET
- Effectiveness of Fluticasone Furoate–Vilanterol for COPD in Clinical Practice
- (2016) Jørgen Vestbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Indacaterol–Glycopyrronium versus Salmeterol–Fluticasone for COPD
- (2016) Jadwiga A. Wedzicha et al. NEW ENGLAND JOURNAL OF MEDICINE
- The lung function profile of once-daily tiotropium and olodaterol via Respimat® is superior to that of twice-daily salmeterol and luticasone propionate via Accuhaler® (ENERGITO® study)
- (2016) Kai Michael Beeh et al. International Journal of Chronic Obstructive Pulmonary Disease
- Association of Inhaled Corticosteroids with Incident Pneumonia and Mortality in COPD Patients; Systematic Review and Meta-Analysis
- (2015) Emir Festic et al. COPD-Journal of Chronic Obstructive Pulmonary Disease
- Efficacy and safety of fluticasone furoate/vilanterol (50/25 mcg; 100/25 mcg; 200/25 mcg) in Asian patients with chronic obstructive pulmonary disease: a randomized placebo-controlled trial
- (2015) Jinping Zheng et al. CURRENT MEDICAL RESEARCH AND OPINION
- Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations
- (2015) James F. Donohue et al. RESPIRATORY MEDICINE
- Efficacy and tolerability of budesonide/formoterol added to tiotropium compared with tiotropium alone in patients with severe or very severe COPD: A randomized, multicentre study in East Asia
- (2015) Sang-Do Lee et al. RESPIROLOGY
- Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial
- (2015) Dave Singh et al. BMC Pulmonary Medicine
- Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation
- (2015) L. Shamseer et al. BMJ-British Medical Journal
- Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation
- (2015) L. Shamseer et al. BMJ-British Medical Journal
- LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD
- (2015) Santanu Sannigrahi et al. International Journal of Chronic Obstructive Pulmonary Disease
- Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular risk
- (2015) Henry Covelli et al. International Journal of Chronic Obstructive Pulmonary Disease
- Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials
- (2015) Steven Pascoe et al. Lancet Respiratory Medicine
- Long-Acting Bronchodilators and Arterial Stiffness in Patients With COPD
- (2014) Jean-Louis Pepin et al. CHEST
- Use of Inhaled Corticosteroids in Patients With COPD and the Risk of TB and Influenza
- (2014) Yaa-Hui Dong et al. CHEST
- INSTEAD: a randomised switch trial of indacaterolversussalmeterol/fluticasone in moderate COPD
- (2014) Andrea Rossi et al. EUROPEAN RESPIRATORY JOURNAL
- Withdrawal of Inhaled Glucocorticoids and Exacerbations of COPD
- (2014) Helgo Magnussen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Extrafine beclomethasone/formoterol in severe COPD patients with history of exacerbations
- (2014) J.A. Wedzicha et al. RESPIRATORY MEDICINE
- A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD
- (2013) Edward M. Kerwin et al. RESPIRATORY MEDICINE
- Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: A randomised trial
- (2013) Fernando J. Martinez et al. RESPIRATORY MEDICINE
- Budesonide/formoterol via Turbuhaler® versus formoterol via Turbuhaler® in patients with moderate to severe chronic obstructive pulmonary disease: Phase III multinational study results
- (2013) Yoshinosuke Fukuchi et al. RESPIROLOGY
- Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials
- (2013) Mark T Dransfield et al. Lancet Respiratory Medicine
- Effects of mometasone furoate/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52-week Phase III trial in subjects with moderate-to-very severe COPD
- (2012) Dennis Doherty et al. International Journal of Chronic Obstructive Pulmonary Disease
- Efficacy and safety of a fixed-dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52-week Phase III trial
- (2012) Ken Kauffman et al. International Journal of Chronic Obstructive Pulmonary Disease
- Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials
- (2012) Ken Kauffman et al. International Journal of Chronic Obstructive Pulmonary Disease
- Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol–fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study
- (2012) Claus F Vogelmeier et al. Lancet Respiratory Medicine
- Effect of fluticasone propionate/salmeterol on arterial stiffness in patients with COPD
- (2011) Mark T. Dransfield et al. RESPIRATORY MEDICINE
- Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: A randomized controlled study
- (2011) Ki Suck Jung et al. RESPIRATORY MEDICINE
- Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD
- (2011) Nicola A. Hanania et al. RESPIRATORY MEDICINE
- Effect of budesonide/formoterol pMDI on COPD exacerbations: A double-blind, randomized study
- (2011) Amir Sharafkhaneh et al. RESPIRATORY MEDICINE
- Beclomethasone/formoterol in the management of COPD: A randomised controlled trial
- (2010) P.M.A. Calverley et al. RESPIRATORY MEDICINE
- Efficacy and Tolerability of Budesonide/Formoterol Added to Tiotropium in Patients with Chronic Obstructive Pulmonary Disease
- (2009) Tobias Welte et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Long-term Use of Inhaled Corticosteroids and the Risk of Pneumonia in Chronic Obstructive Pulmonary Disease
- (2009) Sonal Singh et al. ARCHIVES OF INTERNAL MEDICINE
- Effect of Fluticasone Propionate/Salmeterol (250/50) on COPD Exacerbations and Impact on Patient Outcomes
- (2009) Antonio Anzueto et al. COPD-Journal of Chronic Obstructive Pulmonary Disease
- Efficacy and Tolerability of Budesonide/Formoterol in One Hydrofluoroalkane Pressurized Metered-Dose Inhaler in Patients with Chronic Obstructive Pulmonary Disease
- (2009) Stephen I. Rennard et al. DRUGS
- Budesonide and the risk of pneumonia: a meta-analysis of individual patient data
- (2009) Don D Sin et al. LANCET
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
- (2009) David Moher et al. PLOS MEDICINE
- Efficacy and Safety of Budesonide and Formoterol in One Pressurized Metered-Dose Inhaler in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease
- (2008) Donald P Tashkin et al. DRUGS
- Effect of fluticasone propionate/salmeterol (250/50μg) or salmeterol (50μg) on COPD exacerbations
- (2008) Gary T. Ferguson et al. RESPIRATORY MEDICINE
- The Prevention of Chronic Obstructive Pulmonary Disease Exacerbations by Salmeterol/Fluticasone Propionate or Tiotropium Bromide
- (2007) Jadwiga A. Wedzicha et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now